HBV-specific cytotoxic T-lymphocyte (CTL) activity has a very important role in hepatitis B virus clearance. Present studies suggest that Tapasin, a endoplasmic reticulum (ER) chaperone, stabilizes the peptide-receptive MHC I conformation, allowing peptide exchange and increasing more peptides to be translocated into the ER. We have previously testified that cytoplasmic transduction peptide (CTP)-HBcAg 18-27 -Tapasin fusion protein could enter cytoplasm of dendritic cells, and enhance T cells' response to generate specific CTLs efficiently in vitro. In the present study, we evaluated specific immune responses of CTP-HBcAg 18-27 -Tapasin fusion protein in HLA-A2 transgenic mice (H-2K b ) and anti-viral ability in HBV transgenic mice, and explored the mechanisms probably involved in. The studies showed that CTP-HBcAg 18-27 -Tapasin not only increased production of cytokine IFN-g and interleukin-2 (IL-2), compared with CTP-HBcAg 18-27 , HBcAg 18-27 -Tapasin, and PBS, but also significantly induced the higher percentages of IFN-g þ CD8 þ T cells and specific CTL responses in HLA-A2 transgenic mice. Moreover, enhancement of specific CTL activity induced by the fusion protein reduced HBV DNA and hepatitis B surface antigen (HBsAg) levels and decreased the expression of HBsAg and hepatitis B core antigen (HBcAg) in liver tissue of HBV transgenic mice. In addition, CTP-HBcAg 18-27 -Tapasin could upregulate the expression of JAK2, Tyk2, STAT1, and STAT4 in T lymphocytes in HLA-A2 transgenic mice splenocytes. However, there was no significant difference on the expressions of JAK1, JAK3, and STAT6 between each group. In conclusion, CTP-HBcAg 18-27 -Tapasin fusion protein could enhance not only the percentages of CTLs but also induce robust specific CTL activity and inhibits hepatitis B virus replication in vivo, which was associated with activation of the JAK/STAT signaling pathway. Hepatitis B virus (HBV) infection remains a global problem, despite the effectiveness of the HBV vaccines in preventing infection. Although the factors that contribute to the clearance of the virus in acute self-limiting HBV infection or to the persistence of the virus in chronic HBV infection are not completely clear, increasing evidence suggests that host immune responses are an important factor in determining the outcome of HBV infection. 1,2 Acute individuals develop a strong, polyclonal, multispecific cytotoxic T-lymphocyte (CTL) response and a polyclonal T helper (Th) cell response to the virus typically, while these responses are markedly attenuated in chronically infected patients. 3,4 Persistent HBV infection is characterized by a weak adaptive immune response, thought to be due to inefficient CD4 þ T-cell priming in the early stage of virus infection and subsequent development of a quantitatively and qualitatively ineffective CD8 þ T-cell response. Studies of HBV infection in woodchucks and chimpanzees, as well as patients, are suggesting that multiple and frequent administration of the vaccine may be advisable in treatment of chronic hepatitis. Chronically infected individuals usually exhibit the immune tolerance to targeted antigens. 5 In short, HBV-specific CTL activity has the key role in controlling the outcome of HBV infection because the magnitude of the T-cell response is a critical factor in determining viral control. [6] [7] [8] [9] 
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CD8
þ T cells recognize antigenic peptides presented by MHC I molecules on the surface of APCs or target cells. Folding of MHC I molecules and loading with an appropriate peptide require the assistance of a number of chaperones present in the endoplasmic reticulum (ER), including protein disulfide isomerase, calnexin, calreticulin, ERp57, Tapasin, and the TAP, the latter four forming the peptide-loading complex (PLC). 10, 11 Crystal structures of MHC I and molecular dynamic simulation studies suggest that Tapasin stabilizes the peptide-receptive MHC I conformation, allowing peptide exchange and increasing the probability of loading slow off-rate peptides. In the absence of Tapasin, MHC I molecules can be loaded with fast off-rate suboptimal peptides that can be lost before reaching the cell surface. 12, 13 The low surface expression of MHC I molecules resulted in impaired positive and negative thymic T-cell selection, resulting in a reduction of CD8 þ T-cell number in the thymus and periphery, and reduced antigen presentation to T cells, resulting in poor in vivo CTL response to influenza virus. 14, 15 HBcAg 18-27 epitope (HBcAg [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] ) is a widely accepted as a CTL epitope to stimulate CTL response to hepatitis B core antigen (HBcAg). 16, 17 However, HBV-specific CTL responses induced by exogenous antigens such as HBV-encoded antigens are usually weak, mainly because of the prohibition of intracellular delivery of antigens and peptides by the lipophilic nature and selective permeability of biological membranes. 18 Cytoplasmic transduction peptide (CTP) was deliberately designed to ensure the efficient cytoplasmic delivery of the CTP-fused biomolecules. Thus, combining the specificity of HBcAg CTL epitope, the cell-penetrating property of CTP, and chaperone Tapasin may elicit robust specific HBV immune responses. We have previously testified that the expressed and purified recombinant CTP-HBcAg 18-27 -Tapasin fusion protein could enter the cytoplasm of dendritic cells, and enhance T cells' response to generate specific CTLs efficiently in vitro. 19 In the present study, we investigated whether the CTP-HBcAg 18-27 -Tapasin fusion protein was able to enhance HBV-specific CTL immune responses and anti-viral immunity in vivo.
MATERIALS AND METHODS Reagents, Cells, and Fusion Proteins
The fluorescent antibodies and isotype controls were purchased from eBioscience (USA), and ELISA kits for IFN-g and interleukin-2 (IL-2) were purchased from R&D (USA). All antibodies were purchased from Abcam (UK). Hepatitis B surface antigen (HBsAg) was determined quantitatively using the IMX System (USA) according to the manufacturer's instructions. The levels of HBV DNA were detected by realtime fluorescent quantitation PCR assay kits (PG Biotech, China). Phorbol 12-myristate 13-acetate (PMA), ionomycin, monensin, phytohemagglutinin (PHA), and concanavalin A (ConA) were obtained from Sigma (USA). Soluble fusion proteins CTP-HBcAg 18-27 -Tapasin, CTP-HBcAg [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , and HBcAg 18-27 -Tapasin were purified and had undetectable endotoxin level according to our former experiments (Figures 1a and b) . 19 
EL-4 cells (H-2K b
; from ATCC) were cultured in Dulbecco's modified Eagle's medium containing 10% FBS at 37 1C under a humidified condition of 5% CO 2 and 100 U/ml penicillin.
HBV Transgenic Mice and Immunization C57BL/6-HBV1.3 HBV transgenic mice, which contain 1.3 times over-length of the ayw subtype of the HBV genome, were obtained from the Key Liver Army Laboratory (The No. 458 Hospital, Guangzhou, China), were at 6-8 weeks of age, and were weighing between 20 and 23 g. The characterization of the mice has been described in detail previously, 20, 21 and maintained in the experiment animal center of Shanghai No.6 Hospital under specific pathogen-free conditions. All experiments were approved by the laboratory animal ethical commission of Shanghai Jiao tong University. Mice were divided into six groups, with six mice in each group. Mice were immunized intramuscularly in the left tibialis anterior muscle three times at 1-week intervals with PBS, CTP-HBcAg 18-27 -Tapasin (50 mg, 100 mg), CTP-HBcAg 18-27 (50 mg), HBcAg 18-27 -Tapasin (50 mg), and IFN-a (20 000 IU). Mice were killed, and serum samples, splenocytes, and livers were collected at day 7 after the third immunization.
HLA-A2 Transgenic Mice (H-2K
b ) and Immunization HLA-A2 transgenic mice (H-2K b ), 6-8 weeks old, which have the murine b2-microglobulin (b2m) and H-2D b genes knocked out, and are transgenic for a chimeric human HLA-A2.1 expressing the a1 and a2 domains of HLA-A2.1 and a mouse H-2D b -derived a3 domain to allow their interaction with mouse CD8, 22 were purchased from Jackson Laboratory (USA) and maintained in the experiment animal center of Shanghai No. 6 Hospital under specific pathogen-free conditions. Mice were divided into four groups, with six mice in each group. Mice were immunized subcutaneously at the tail base one time at 1-week intervals with 20 mg CTPHBcAg 18-27 -Tapasin, 20 mg CTP-HBcAg 18-27 , 20 mg HBcAg 18-27 -Tapasin, and PBS, respectively. Mice were killed, and splenocytes were collected at day 7 after the third immunization.
Measurement of IFN-g Production by Intracellular Cytokine Staining to Splenocytes
To evaluate the percentages of IFN-g-secreting cells at the individual cell level of HBV transgenic mouse splenocytes, single-cell suspensions from spleens were analyzed by flow cytometry. Splenocytes were stimulated in the presence of 10 mg/ml HBcAg for 6 h. After incubation for 3 h, 25 mg/ml of PMA, 1 mg/ml of ionomycin, and 1.7 mg/ml of monensin were added and incubation continued for another 3 h. 23 After washing with PBS, cells were stained with saturating concentrations of PE-conjugated anti-CD8a McAb. After being fixed with Fix and Perm reagents A and B (BD Biosciences, USA), the cells were incubated for 20 min with FITC-labeled anti-IFN-g McAb, followed by washing two times with PBS and analyzing by flow cytometry. Fluorescence analyses were performed on Coulter EPICS XL Flow Cytometer (Beckman) using the Expo32-ADC software.
Serological Analysis and Determination of Serum HBV DNA and HBsAg Serum HBV DNA and HBsAg levels were determined after the second and third immunization by a quantitative polymerase chain reaction (PCR) and Abbott kits, respectively. 24 Detection limit of the PCR was 1000 genomic copies per ml. The limit of detection for HBsAg was 0.28 ng/ml. We examined the inhibitory rate of HBV DNA and HBsAg induced by fusion protein. ALT and AST activities were measured by ARCHITECT Automatic Biochemistry Analyzer. The reference concentrations for serum HBV-DNA and HBsAg are copy/ml and ng/ml.
Histology and Immunohistochemistry of the Liver
Liver samples from the mice at day 7 after the third immunization were fixed in formaldehyde and embedded in paraffin.
Deparaffinized 3-5-mm-thick sections were stained by hematoxylin-eosin (HE). For histological analysis, deparaffinized 3-5-mm-thick sections of the liver tissue were treated with 0.3% H 2 O 2 in methanol for 10 min to eliminate the endogenous peroxidase activity, rinsed with distilled water, and immersed in PBS for 5 min. After the sections were blocked with normal goat serum for 30 min at room temperature, a goat anti-HBsAg polyclonal antibody and a goat anti-HBcAg polyclonal antibody (Novus Biologicals, USA) was applied overnight at 4 1C, and following three times of washing in PBS, sections were incubated for 30 min with biotinyated secondary antibody (Boster, China) at 37 1C and then for 30 min with streptavidinbiotin-peroxidase complex before being revealed by diaminobenzidine (DAB) and counterstained with hematoxylin. 21 The Levels of Cytokine IFN-g and IL-2 Splenocytes (2 Â 10 6 cells/ml) harvested from immunized HLA-A2 transgenic mice were cultured in 24-well plates at 37 1C in the presence of 10mg/ml HBcAg (CalBioreagents, USA). After 72 h incubation, culture supernatant concentrations CTP-HBcAg 18-27 -Tapasin induces HBV-specific CTLs X Chen et al of IFN-g and IL-2 were determined using R&D.ELISA kits following the instructions provided by the manufacturer. The concentrations of cytokines in the samples were determined from the standard curves. Data are expressed as pg/ml.
Measurement of Interferon-g Production by Intracellular
Cytokine Staining Cell staining and flow cytometry were performed with reagents according to the manufacturer's protocols. The splenocytes from the HLA-A2 transgenic mice were stimulated in vitro for 6 h in cRPMI-1640 medium with 10 mg/ml HBcAg, PMA, ionomycin, and monensin at the concentrations described above. The cells were then harvested, and the intracellular cytokines were detected by flow cytometry as the mentioned above.
T-Lymphocyte Generation
Mixed lymphocytes were derived from splenocytes of HLA-A2 transgenic mice, which were treated using lymphocyte separation liquid (Beijing Combi Source Technology, China). T lymphocytes were derived from the above-mixed lymphocytes using nylon wool columns (Wako). Single-cell suspensions of lymphocytes (2 Â 10 6 cells per well) were grown in six-well plates. The purity of the isolated T cells was determined by flow cytometry after staining with anti-CD3-PE-Cy5 (eBioscience, San Diego, CA, USA), and the samples purity 480% were used for this experiment.
CTL Assay and T-Lymphocyte Proliferation Activity Assay T lymphocytes (5 Â 10 6 /ml) from HLA-A2 transgenic mice were used as effectors, and the EL-4 cells pulsed with 10 mg/ml HBcAg 18-27 was used as target cells. 25 EL-4 cells were seeded at a density of 5 Â 10 4 cells per well in 96-well plates. Effector cells were incubated with EL-4 at different effector and target (E/T) ratios (5:1, 10:1 or 20:1) at 37 1C under 5% CO 2 for 4 h. The specific CTL activity was measured using a CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, Madison WI, USA) for lactate dehydrogenase (LDH) release according to the manufacturer's instructions. The absorbance values of the supernatants were recorded at optical density 490 nm. Percent cytotoxicity was calculated as follows: ((experimental release À effector spontaneous release À target spontaneous release)/(target maximum release À target spontaneous release)) Â 100%. 19, 26 In this study, by using the ConA-induced T-lymphocyte proliferation, we assessed proliferation activity of T lymphocytes. Because ConA promotes cell mitogen, it mainly stimulates the effect on T lymphocytes. The above T lymphocytes (2 Â 10 6 cells/ml) were cultured in 96-well culture plates in a final volume of 200 ml in the presence of 1 mg ConA solution at 37 1C under 5% CO 2 for 48 h, and 20 ml Cell Counting Kit-8 solution (Beyotime Institute of Biotechnology, Haimen, China) was added to the plates at 37 1C under 5% CO 2 for 4 h. The absorbance was finally read at 450 nm.
Enzyme-Linked Immunospot Assay
HBcAg 18-27 -specific CD8 þ T cells were enumerated using enzyme-linked immunospot (ELISPOT). 27 Splenocytes obtained from vaccinated transgenic mice (HBV transgenic mice and HLA-A2 transgenic mice), at 1 Â 10 6 in a volume of 100 ml, were added to ImmunoSpot plates (Dakewe, China) precoated with anti-IFN-g McAb (BD, USA). Then, the HBcAg 18-27 peptide (10 mg/ml) was added to each well. A positive control (15 mg/ml, PHA) and a 'no-peptide' negative control were included in all assays. The plates were incubated overnight at 37 1C in a 5% humidity incubator. After incubation, the wells were washed two times with deionized water and three times with wash buffer (1 Â PBS þ 0.05% Tween-20). The wells were then stained with saturating concentrations of biotin-conjugated anti-IFN-g McAb (BD) at 37 1C for 1 h. After washing three times, streptavidin-alkaline phosphatase was added to each well, and the plates were incubated for 1 h at room temperature. The plates were again washed three times. Thirty microliters of activator solution (Dakewe, China) were added to develop spots. After 10 to 30 min, the plates were washed with distilled water to stop the reaction. Experiments were performed in triplicate. After being air dried, the number of spots in each well was counted using the Bioreader 4000 PRO-X (Biosys).
Analysis of Related Molecule mRNA Levels of JAK/STAT Pathway by Real-Time PCR
The above harvested T cells were collected for total RNA isolation according to the protocol for Trizol Reagent (Invitrogen, CA). cDNA was generated using PrimeScript 1st Strand cDNA Synthesis Kit (TaKaRa, Japan). Relative quantitative real-time PCR was performed using SYBRs Premix Ex TaqTM reagents (TaKaRa, Japan) on a LightCycler (Roche Diagnostic). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal reference. The PCR primers used were as follows: JAK1 forward, 5 (Figure 2) . Thus, Tapasin fused with CTP-HBcAg 18-27 could induce more efficiently T-cell immune response than CTP-HBcAg [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] or HBcAg 18-27 -Tapasin in vivo.
Liver sections were evaluated primarily in terms of inflammatory cell infiltration. There were few lymphocytes in the liver of mice immunized with PBS. However, the amounts of lymphocytes were increased significantly in the liver of mice treated with HBcAg 18-27 -Tapasin, CTP-HBcAg 18-27 , IFN-a, and CTP-HBcAg 18-27 -Tapasin. A larger number of lymphocyte infiltration appeared in the liver of mice immunized with CTP-HBcAg 18-27 -Tapasin (Figure 3a) . Furthermore, the results suggested histological changes in the liver were related with the intracellular expression of IFN-g in CD8 þ T cells. 
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HBcAg 18-27 -Tapasin, or IFN-a (*Po0.05). It was worth noting that 100 mg CTP-HBcAg 18-27 -Tapasin immunization decreased remarkably the level of HBsAg and HBV DNA in sera than that with 50 mg CTP-HBcAg 18-27 -Tapasin did (*Po0.05). Meanwhile, the AST and ALT in sera of mice treated with 100 mg CTP-HBcAg 18-27 -Tapasin was significantly higher than those in 50 mg CTP-HBcAg 18-27 -Tapasin group (*Po0.05) (Figures 4c and d) .
To further confirm the therapeutic effects of fusion proteins in transgenic mice, immunohistological analysis was performed in livers from the above various treatment groups. A large number HBsAg and HBcAg were detected (stained brownish yellow) in the cytoplasm of hepatocytes in mice treated with 1 Â PBS. CTP-HBcAg 18-27 -Tapasin immunization reduced the HBsAg and HBcAg level in a dose-dependent manner, and HBsAg and HBcAg expression was very low with 100 mg CTP-HBcAg 18-27 -Tapasin treatment (Figures 3b and c) .
CTP-HBcAg 18-27 -Tapasin Stimulates the Secretion of Cytokine IFN-g and IL-2
Splenocytes from immunized HLA-A2 transgenic mice were assayed for the secretion of the cytokines IFN-g, IL-2 (Th1-like) upon restimulation with HBcAg. As shown in Figure 5 , splenocytes from immunized animals with CTP-HBcAg 18-27 -Tapasin produced higher levels of IFN-g (310.6 ± 1.51 pg/ml) and IL-2 (506.42 ± 5.79 pg/ml). However, there were no significant differences on the levels of IFN-g and IL-2 between other groups (P40.05). To confirm the modulating role of CTP-HBcAg 18-27 -Tapasin fusion protein in cell-mediated immune responses, we further analyzed the ability of specific CTL. As shown in Figure 6b , the specific cytolysis percentages for CTP-HBcAg 18-27 -Tapasin CTP-HBcAg 18-27 -Tapasin induces HBV-specific CTLs X Chen et al immunized mice were 53.24±1.34%, 31.17±2.46%, and 18.54±3.54% for ratios of effector/target (E/T) of 20:1, 10:1, and 5:1, respectively. In contrast, specific cytolysis percentages were 23.09 ± 2.76%, 21.06 ± 3.77%, and 11.10 ± 6.40%, respectively, in CTP-HBcAg 18-27 groups for all effector/target (E/T) ratios. However, the CTL killing activity between HBcAg 18-27 -Tapasin and PBS had no significant difference. These results suggested that CTP-HBcAg 18-27 -Tapasin induced specific CTL activities, which was consistent with the high level of IFN-g expressed in CD8 þ T cells. Meanwhile, we further analyzed the ability of T-lymphocyte proliferation in different groups. CTP-HBcAg 18-27 -Tapasin enhanced significantly T-lymphocyte proliferation activity, which was higher than control groups (Figure 6c ).
CTP-HBcAg 18-27 -Tapasin Boosted the Number of Specific CD8
þ T Cells Elicited in vivo HBcAg 18-27 -specific T cells were enumerated by measuring IFN-g-producing cells by ELISPOT assay. As shown in CTP-HBcAg 18-27 -Tapasin enhances JAK2, Tyk2, STAT1, and STAT4 Expression To explore the involved mechanisms, we found CTPHBcAg 18-27 -Tapasin had an effect on JAK/STAT signaling pathway. We further analyzed the JAK1, JAK2, JAK3, Tyk2, STAT4, STAT1, and STAT6 expression in different groups. The results revealed that expression of JAK 2, Tyk2, STAT1 and STAT4 was significantly upregulated in HLA-A2 transgenic mice immunized with CTP-HBcAg 18-27 -Tapasin group compared with CTP-HBcAg 18-27 , HBcAg 18-27 -Tapasin, and PBS group. However, the expressions of JAK1, JAK3, and STAT6 are no statistical difference in mice immunized with all of fusion proteins or PBS (P40.05) (Figure 8 ).
DISCUSSION
The development of novel immunotherapy has been highly anticipated because HBV infection is one of the leading causes of cirrhosis or hepatocellular carcinoma-related death. 
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Several studies have demonstrated that the main cause of viral persistence during HBV infection is an inadequate anti-viral immune response to the viral antigens. 28, 29 The viral-specific CD8 þ T-cell response have an important role in the process of viral clearance. Patients with chronic hepatitis B (CHB) or therapeutic failure show deficient Th1 immunity associated with inefficient CD8 þ T-cell cytotoxicity. 30, 31 Therefore, induction of Th1 immunity and CTL responses specific to HBV represents a promising strategy to protect against HBV infection. CD8 þ T cells recognize antigenic peptides presented by MHC I molecules on the surface of APCs or target cells. The presentation of mainly proteasomal degradation products on MHC I molecules at the cell surface is a way to carry information about the cellular proteome to CTLs. 32, 33 Efficient antigen processing via MHC I relies on the PLC, consisting of the heterodimeric transporter associated with antigen processing (TAP) as centerpiece, which recruits the peptidereceptive MHC I heavy-chain/b 2 -microglobulin dimer by the adapter protein Tapasin. The type I membrane protein Tapasin fulfills various functions within the PLC. Its ER-lumenal domain binds to MHC I and its transmembrane domain to a specific interaction scaffold in TAP1 and TAP2, thereby connecting the peptide supplier TAP and the peptide acceptor MHC I. 32, 34 Tapasin acts as peptide editor/ facilitator, promoting the binding of immunodominant peptides. 35 According to current models, peptide exchange is accelerated by Tapasin and low-affinity peptides dissociate faster. 36, 37 The protein transduction domain (PTD) of HIV-1 TAT has been extensively documented with regard to its membrane transduction potential, as well as its efficient delivery of biomolecules in vivo. However, the majority of PTD and PTD-conjugated molecules translocates to the nucleus rather than to the cytoplasm after transduction, owing to the functional nuclear localization sequence (NLS). 38, 39 A new approach that appears to be the safest is to produce recombinant proteins exogenously and then deliver them systemically or by localized injections into the target cells or tissues. In comparison with PTD, CTP and its fusion partners exhibited a clear preference for cytoplasmic localization, and also markedly enhanced membrane transduction potential. 39, 40 By constructing recombinant protein and cell-penetrating peptide, different proteins and polypeptides were delivered into a variety of cells in vivo and in vitro. 41, 42 HBcAg 18-27 epitope has been shown to be able to induce HBV-specific CTL response and thus is a potential for the therapeutic design of chronic HBV infection. 16, 17 In the present study, we expressed HBcAg [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] included the complete amino-acid sequences that were fused with CTP and Tapasin. Meanwhile, our previous results showed that recombinant CTP-HBcAg 18-27 -Tapasin could penetrate into CTP-HBcAg 18-27 -Tapasin induces HBV-specific CTLs X Chen et al DCs cytoplasm. 19 On the basis of this mechanism, we used CTP as a tool for the efficient delivery of Tapasin and antigen to APCs and to induce more HBV-specific CD8 þ T cells.
HBV transgenic mice are immunologically tolerant to HBV-encoded antigens and represent a model of chronic HBV infection suitable to assess the anti-viral potential of immunotherapeutic strategies to break tolerance and terminate persistent HBV infection. Meanwhile, these mice do not develop chronic hepatitis because they are immunologically tolerant to viral antigens. Several studies have also illustrated that activated CTLs and secreted cytokines might effectively downregulate HBV gene expression and even control viral replication. 43 At 1 week after the administration of the last treatment to HBV transgenic mice, the hepatocytes appeared swollen and there were lymphocyte infiltration and hyperemia in the liver tissue of mice from CTP-HBcAg 18-27 -Tapasin fusion protein group. In contrast, these histological changes were not apparent in the mice from other fusion protein groups, although there was also minimal lymphocyte infiltration in the mice from PBS and CTP-HBcAg [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] and HBcAg 18-27 -Tapasin fusion protein groups. CTPHBcAg 18-27 -Tapasin also enhanced the percentages of IFN-gproducing CD8
þ T cells in the spleen of HBV transgenic 20 However, our results suggested that CTPHBcAg 18-27 -Tapasin increased the percentages of IFN-gproducing CD8
þ T cells in the spleen, enhanced the cytokine IFN-g, IL-2 (Th1-like) secretion, and specific CTL activity. These indicated that the modification of Tapasin could enhance the presentation of target antigens via intracellular delivery to CD8 þ T cells, and induce stronger cellular immune responses.
To further investigate CTP-HBcAg 18-27 -Tapasin can boost the HBcAg 18-27 -specific CD8 þ T cells elicited in vivo, we tested it through the ELISPOT assay. 27 The results showed that a substantial number of T cells harvested from mice immunized with the CTP-HBcAg 18-27 -Tapasin responded by producing IFN-g. The responses observed indicate that CTP-HBcAg 18-27 -Tapasin was found to generate strong HBcAg 18-27 -specific T-cell responses by virtue of their ability to induce increased frequencies of IFN-g-producing T cells compared with control group. This result was consistent with the result of the intracellular expression of IFN-g in CD8 þ T cells analyzed by flow cytometry. Taken together, these results indicate that the CTP-HBcAg 18-27 -Tapasin fusion protein could induce HBcAg 18-27 -specific CTL responses.
The above results indicated that HBcAg 18-27 via CTP transduction could efficiently induce the cytokine IFN-g, IL-2 (Th1-like) secretion, and our present experiments testified that CTP-HBcAg 18-27 -Tapasin fusion protein could enter the cytoplasm of dendritic cells and increase IL-12p70 production and then enhance cellular immune responses. Some studies have demonstrated that complete response to anti-viral treatment was correlated with predominant Th1 responses accompanied with enhanced CTL activity in CHB patients, 29 implying that activation of Thl immunity might be important for the successful treatment of HBV. 44, 45 Thus, activation of Thl immunity was required for CTL activity.
There are several signaling that are required for Th1 cell differentiation. 9 IFN-g signaling activates STAT1 and reinforces the Th1 phenotype in a positive feedback loop. 46, 47 IL-12 signaling induces STAT4, which positively regulates many aspects of the Th1 genetic program. STAT1 and STAT4 also contribute to the regulation of Tbx21 (the gene that encodes T-bet) expression. [46] [47] [48] [49] Therefore, CTP-HBcAg 18-27 -Tapasin could increase IL-12p70 and IFN-g production, which may mediate IL-12/STAT4 and IFN-g/STAT1 signaling pathway. These are required for Th1 cell differentiation and mediated CTL activity indirectly. Therefore, we further analyzed the related molecules levels of JAK/STAT pathway in different groups. The expression of the related molecules mRNA levels was detected by RT-PCR and the proteins expression were detected by western blot analysis. The results revealed that the expression of JAK2, Tyk2, STAT1 and STAT4 was significantly upregulated in HLA-A2 transgenic mice immunized with CTP-HBcAg 18-27 -Tapasin group compared with CTP-HBcAg 18-27 , HBcAg 18-27 -Tapasin, and PBS group. However, the expressions of JAK1, JAK 3, and STAT6 are no statistical difference in mice immunized with all of fusion proteins or PBS. These results indicated that modification of Tapasin on intracellular antigen peptides via CTP transduction could mediate cytokines production and mediated CTL activity indirectly, which were associated with activation of the JAK/STAT signaling pathway.
The HBV transgenic mice we used express K b -and D b -MHC class I molecules and HBcAg [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] is an HLA-A0201-restricted epitope. However, studies showed that the HBcAg 18-27 epitope can elicit responses and was able to be recognized by specific CTL when presented in the context of different HLA-A2 subtypes, although it is immunodominant in the context of HLA-A2.1, indicating that immunization with a peptide based on an HLA supertype epitope can lead to a CTL response in individuals expressing different HLA molecules belonging to the same HLA supertypes. 21, 50, 51 In our study, our results showed that the fusion peptide CTPHBcAg 18-27 -Tapasin could enhance the percentages of IFN-gproducing CD8
þ T cells, and decrease HBV DNA and HBsAg level in serum as well as HBsAg and HBcAg expression in liver tissue. These data further increase the potential coverage and efficacy of therapeutic vaccines based on the HBcAg 18-27 sequence. Therefore, our results might suggest the more broad ability of HBcAg [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] epitope, especially when fused with CTP and Tapasin, in the context of HLA restrictions.
In summary, our results demonstrate that vaccination with soluble CTP-HBcAg 18-27 -Tapasin fusion protein could induce robust strong immune responses in HLA-A2 transgenic mice and therapeutic effects in HBV transgenic mice, which were associated with activation of the JAK/STAT signaling pathway. Therefore, this may be a potential therapeutic strategy for eradicating virus in patients with chronic HBV infection.
